SPS
AVBP icon

Susquehanna Portfolio Strategies’s ArriVent BioPharma AVBP Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Buy
+12,252
New +$277K ﹤0.01% 851
2025
Q3 		– Sell
-20,056
Closed -$437K – 1121
2025
Q2 		$437K Buy
+20,056
New +$416K 0.01% 686

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna Portfolio Strategies's AVBP Position: Q1 2026 in Review

Susquehanna Portfolio Strategies opened a new position in ArriVent BioPharma (AVBP) in Q1 2026: 12,252 shares worth $283K. The stake represents ﹤0.01% of the portfolio and ranks #851 among its holdings. This is a return to the name: Susquehanna Portfolio Strategies previously reported a position in AVBP as recently as Q2 2025.

Susquehanna Portfolio Strategies first reported a position in AVBP in Q2 2025 and has held it in 2 quarters since. The position peaked at $437K in Q2 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Susquehanna Portfolio Strategies held 12,252 shares of ArriVent BioPharma worth $283K as of Q1 2026.
  • ArriVent BioPharma was a new Susquehanna Portfolio Strategies position in Q1 2026.
  • ArriVent BioPharma made up ﹤0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #851 holding.
  • Susquehanna Portfolio Strategies first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 2 quarters since.
  • Susquehanna Portfolio Strategies's ArriVent BioPharma position peaked at $437K in Q2 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.